Symbol="KRBP"
AssetType="Common Stock"
Name="Kiromic BiopharmaÂ Inc"
Description="Kiromic BioPharma, Inc., a gene editing and target discovery company, focuses on the development of immuno-oncology therapies for the treatment of blood cancers and solid tumors. The company is headquartered in Houston, Texas."
CIK="1792581"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="7707 FANNIN ST., SUITE 140, HOUSTON, TX, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="2752400"
EBITDA="-26480300"
PERatio="None"
PEGRatio="None"
BookValue="-8.31"
DividendPerShare="0"
DividendYield="0"
EPS="-55.36"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.914"
ReturnOnEquityTTM="-5.49"
RevenueTTM="0"
GrossProfitTTM="0"
DilutedEPSTTM="-55.36"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="None"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="-"
PriceToBookRatio="15.11"
EVToRevenue="-"
EVToEBITDA="-0.163"
Beta="0.155"
num_52WeekHigh="18.6"
num_52WeekLow="2.19"
num_50DayMovingAverage="2.966"
num_200DayMovingAverage="5.16"
SharesOutstanding="1176300"
DividendDate="None"
ExDividendDate="None"
symbol="KRBP"
open="2.36"
high="2.44"
low="2.24"
price="2.33"
volume="40088.00"
latest_trading_day="2023-08-04"
previous_close="2.34"
change="-0.01"
change_percent="-0.4274%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="56"
trend_strength="Strong Trend"
buying_signal="Strong Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="44"
Volume_recent_avg="255425"
Change_recent_avg="0.01"
Delta_recent_avg="0.6"
Variance_recent_avg="0.3"
Change_ratio_recent_avg="-0.49"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="44"
Aroon_momentum_negative="56"
image_negative_thumbnail_id_1="121"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0055.jpeg"
image_negative_thumbnail_id_2="110"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0066.jpeg"
image_neutral_thumbnail_id_1="551"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0048.jpeg"
image_neutral_thumbnail_id_2="531"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0068.jpeg"
image_positive_thumbnail_id_1="1001"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0163.jpeg"
image_positive_thumbnail_id_2="647"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0061.jpeg"
image_professor_thumbnail_id_1="1169"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0003.jpeg"
image_professor_thumbnail_id_2="1185"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0019.jpeg"
